Journal of International Research in Medical and Pharmaceutical Sciences
 

Journal of International Research in Medical and Pharmaceutical Sciences, ISSN No. : 2395-4477 (Print), 2395-4485 (Online), Vol.: 13, Issue.: 1

Original Research Article

IDENTIFICATION OF PARP1 AS A POTENTIAL THERAPEUTIC TARGET IN TRIPLE NEGATIVE AND BASAL-LIKE BREAST CANCER MOLECULAR SUBTYPES AMONG WEST ALGERIAN PATIENTS

 

IKRAM ZIANE1, AMINA BENDAOUD1, MERIEM KAOUTER BENYELLES1, AMINA BELHADJ1, BELKACEM KELKOUL2, LEILA AMOUCHASE2, MOHAMED BENALI1,3, SORAYA MOULESSEHOUL1,3 AND LYNDA ADDOU-KLOUCHE1,4*

1Department of Biology, University Djillali Liabes of Sidi Bel Abbes, Algeria.

2Anatomy and Pathology Laboratory, Regional Military Hospital, Oran, Algeria.

3Laboratory of Biotoxicology, University Djillali Liabes of Sidi Bel Abbes, Algeria.

4Laboratory of Applied Molecular Biology and Immunology, University Abou Bekr Belkaid of Tlemcen, Algeria.

Abstracts

Purpose: Breast cancer is partly responsible for the therapeutic failures of tumors with the most worsening prognoses. Increasing understanding of the cellular aberrations inherent to cancer cells was an important step towards therapy individualization. Poly (ADP-ribose) polymerase-1 (PARP1) as a promising novel target in breast cancer was an example of this strategy. However, the biological and clinical significance of PARP1 expression and its associations with outcome remain to be defined. We aimed in present study to explore PARP1 expression in breast cancers samples among west Algerian patients.

Materials and Methods: We classified 78 primary breast cancers collected and diagnosed at the Regional Military Hospital of Oran (Algeria) using immunohistochemical biomarkers then; we examined immunohistochemical PARP1 expression and assessed its correlation with clinicopathological parameters and breast cancer molecular subtypes.

Results: PARP1 nuclear overexpression was found in (44, 8%) of all infiltrating breast carcinomas. PARP-1 protein overexpression was associated to higher tumor grade (P=0.036), hormone-negative tumors (P=0.005) and estrogen-negative tumors (P=0.003). Moreover, PARP1 was significantly expressed in Triple-negative (P=0.015) and basal-like breast cancers, but was also present in HER2 positive breast cancers (P=0.014).

Conclusions: Our data highlights the interest of immunohistochemical biomarkers in breast cancer molecular classification. We found that PARP1 overexpression is associated with triple-negative and basal-like tumors and could be a potential therapeutic in these two pejorative breast cancer subtypes. Furthermore, PARP1 overexpression could be a predictive biomarker of therapeutic resistance in HER2 positive tumors.The assessment of PARP1 protein expression may improve the selection of patients for PARP1 inhibitor therapy.

Keywords :

PARP1; triple-negative breast cancer; basal-like; biomarker; targeted therapy.